Amneal Takes Control Of AvKARE In US
Offers Access To Departments Of Defense And Veterans Affairs
Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”
You may also be interested in...
Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.
In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.
Amneal’s new management team is open to negotiating a major transaction, even as it looks to restore organic growth through a greater focus on differentiated generic and hybrid products.